Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Cost of Care

The ASCO Post Staff

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Deborah Collyar: What's In It for Patients?

FDA Approves Label Expansion for Agent Used in Patient Selection for Pre-Taxane Radioligand Therapy

Adding Olanzapine to Triplet Antiemetics Post–Anthracycline/Cyclophosphamide Chemotherapy

Addition of Lenvatinib-Pembrolizumab to Chemotherapy in Advanced/Metastatic Gastroesophageal Adenocarcinoma

Role of Mitochondrial Pathways in Melanoma Progression, Treatment Resistance

FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-Mutated NSCLC